The Indian Pharmaceutical Alliance is working to regularize 'legacy' medicines that have been marketed for years but lack central CDSCO approval. This initiative aims to fix historical documentation gaps for essential drugs. Investors should monitor how this process impacts compliance costs and potential regulatory scrutiny as the sector faces stricter oversight.
The Indian Pharmaceutical Alliance (IPA), which represents 23 of India's leading pharmaceutical companies, is proactively engaging with the Central Drugs Standard Control Organisation (CDSCO) to address a long-standing issue regarding "legacy" drugs. These are medicines that have been manufactured and sold for decades but currently lack formal approval or registration in the central regulatory database.
Root Cause: Historical Licensing Gaps
The discrepancy stems from the way drug licensing was handled historically in India. For many years, products were licensed and approved by state-level drug authorities. Over time, these records were not fully integrated into the central CDSCO registry. As a result, many widely used, single-molecule drugs currently face a documentation gap. While these medicines are technically being sold legally based on state approvals, they lack the specific central registration that current regulations increasingly demand.
Key medicines identified in this effort include essential drugs such as sodium valproate, used to treat epilepsy and bipolar disorder, and carbamazepine, another common anticonvulsant. Both are part of the National List of Essential Medicines (NLEM). Additionally, some strengths of lithium carbonate, a mood stabilizer, also face similar registration discrepancies, as current central records may not reflect the full range of strengths available in the market.
Regulatory Environment and Investor Context
The effort to clean up the national drug registry is happening against a backdrop of increasing regulatory stringency in India. The CDSCO has been working to enhance transparency and oversight, including mandates like the 'One Brand – One Formulation' rule introduced in July 2026. Furthermore, judicial interventions, such as the Delhi High Court's emphasis on 'No Approval, No Market' policies, have heightened the pressure on pharmaceutical companies to ensure every product has a clean, updated regulatory file.
For investors, this regularization push has two main implications. First, there is the aspect of compliance costs. Pharmaceutical companies may need to allocate resources and time to generate or retrieve retrospective clinical data to satisfy central requirements. This could lead to temporary cost increases in the quality and regulatory departments.
Second, there is the risk of market disruption. While these drugs are essential, if a manufacturer cannot successfully bridge the documentation gap, there is a risk that regulators could demand the withdrawal of those specific products from the market. However, given that these are essential medicines, a cooperative approach between the industry and the regulator is the most likely path forward.
Investors should monitor how the government defines the process for this regularization and whether it leads to clear timelines for companies to comply. The key will be how smoothly the industry can integrate these legacy products into the central system without facing product bans or significant penalties.